Listed

Praxis Precision Medicines, Inc.

PRAXNasdaqCIK 1689548HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2025$0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2025, from the 10-K filed Feb 19, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$2.87Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure+13.3% on a year earlier
  • Free cash flow−$77.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$77.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Capital expenditure: $245.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure−42.1% on a year earlier

Last eight quarters

Full statements
Revenue$0Operating margin not reported
Diluted EPS−$2.87, Q2 FY2026
Free cash flow−$77.8m, Q2 FY2026
Praxis Precision Medicines, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.3Revenue, Q3 FY2024, three months to 2024-09-30$302.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure7.5Revenue, Q4 FY2024, three months to 2024-12-31$7.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-05-02, accession 0001689548-25-000058.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-08-04, accession 0001689548-25-000092.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%(18819.5%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$56.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Revenue: $302.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(857.0%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$64.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Revenue: $7.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%(17188.7%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$51.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Revenue: $302.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figure(786.3%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$58.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0001689548-25-000040.Revenue: $7.5m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(2.75)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported (Diluted EPS not reported)(3.29)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$3.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(3.31)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$3.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure(3.36)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$3.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001689548-25-000111.Report this figurenot reported (Diluted EPS not reported)(3.20)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(2.87)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$2.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001689548-26-000083.Report this figure
Free cash flow$m(27.5)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$27.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure(56.1)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$56.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(53.0)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$53.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(54.7)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$54.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Capital expenditure: $56.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure(65.1)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$65.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001689548-25-000111. Derived: 9-month figure less the 6-month figure.Report this figure(76.3)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$76.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029. Derived: 12-month figure less the 9-month figure.Report this figure(86.2)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$86.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Capital expenditure: $62.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001689548-26-000047.Report this figure(77.8)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$77.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Capital expenditure: $245.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001689548-26-000083. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$0Operating margin not reported
Diluted EPS−$13.48, FY2025
Free cash flow−$249.1m, FY2025
Praxis Precision Medicines, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$mnot reported (Revenue not reported)0.0Revenue, FY2022, twelve months to 2022-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-05, accession 0001689548-24-000034.Report this figure2.4Revenue, FY2023, twelve months to 2023-12-31$2.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure8.6Revenue, FY2024, twelve months to 2024-12-31$8.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure0.0Revenue, FY2025, twelve months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue of zero not reported)(5164.4%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$126.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029.Revenue: $2.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(2340.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$200.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029.Revenue: $8.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figurenot reported (Revenue of zero not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue of zero not reported)(5037.9%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$123.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029.Revenue: $2.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(2137.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$182.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001689548-26-000029.Revenue: $8.6m. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figurenot reported (Revenue of zero not reported)
Diluted EPS$ per share(3.94)Diluted EPS, FY2021, twelve months to 2021-12-31−$3.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-02-07, accession 0001689548-23-000044.Report this figure(69.65)Diluted EPS, FY2022, twelve months to 2022-12-31−$69.65 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-05, accession 0001689548-24-000034.Report this figure(18.69)Diluted EPS, FY2023, twelve months to 2023-12-31−$18.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(10.21)Diluted EPS, FY2024, twelve months to 2024-12-31−$10.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(13.48)Diluted EPS, FY2025, twelve months to 2025-12-31−$13.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure
Free cash flow$m(126)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$124.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-02-07, accession 0001689548-23-000044.Capital expenditure: $1.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-02-07, accession 0001689548-23-000044.Report this figure(185)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$185.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-05, accession 0001689548-24-000034.Capital expenditure: $444.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-05, accession 0001689548-24-000034.Report this figure(111)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$111.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029.Capital expenditure: $50.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(132)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$131.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure(249)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$249.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001689548-26-000029.Capital expenditure: $56.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001689548-26-000029.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

Praxis Precision Medicines, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2021-10-06BSOF Parallel Master Fund L.P.10% owner Sale400,000$17.50$7.0mForm 4
2021-10-05BSOF Parallel Master Fund L.P.10% owner Sale23,946$19.15$458.6kForm 4
2021-10-01BSOF Parallel Master Fund L.P.10% owner Sale22,600$19.13$432.3kForm 4
2021-08-23BSOF Parallel Master Fund L.P.10% owner Sale771$20.04$15.5kForm 4
2021-08-23BSOF Parallel Master Fund L.P.10% owner Sale351,625$19.00$6.7mForm 4
2021-08-18BSOF Parallel Master Fund L.P.10% owner Sale3,000$15.88$47.6kForm 4
2021-08-12BSOF Parallel Master Fund L.P.10% owner Sale10,060$13.92$140.0kForm 4
2021-08-11BSOF Parallel Master Fund L.P.10% owner Sale17,222$15.03$258.8kForm 4
2021-08-03BSOF Parallel Master Fund L.P.10% owner Sale22,300$14.99$334.3kForm 4
2021-08-02BSOF Parallel Master Fund L.P.10% owner Sale40,000$15.78$631.2kForm 4
2021-07-30BSOF Parallel Master Fund L.P.10% owner Sale15,854$15.68$248.6kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Praxis Precision Medicines, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Jupiter Topco LLC2026-06-30$1.15bn3,421,374Not compared
JANUS HENDERSON GROUP PLC2026-03-31$1.11bn3,458,863Not compared
FMR LLC2026-06-30$775.7m2,316,907Added+155,964
BlackRock, Inc.2026-06-30$767.5m2,292,585Reduced−32,344
PERCEPTIVE ADVISORS LLC2026-06-30$681.6m2,035,986Unchanged
BAKER BROS. ADVISORS LP2026-06-30$587.0m1,753,198Unchanged
Orbis Allan Gray Ltd2026-06-30$512.2m1,529,788Reduced−942,692
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$447.0m1,335,185Added+578,437
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$413.6m1,235,299Added+13,355
STATE STREET CORP2026-06-30$343.7m1,026,443Added+142,205

Recent filings

All 504 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Praxis Precision Medicines, Inc., recent filings
FiledFormWhat it isAccession number
2026-08-0608:32 ET10-QQuarterly reportPeriod 2026-06-300001689548-26-000083
2026-08-0608:31 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001689548-26-000082
2026-07-0717:05 ET8-K8.01 Other events0001689548-26-000072
2026-07-0216:30 ET8-K4.01 Change of auditor; 9.01 Financial statements and exhibits0001104659-26-080356
2026-06-2916:40 ET8-K8.01 Other events0001689548-26-000069
2026-06-2216:43 ET8-K8.01 Other events0001689548-26-000066
2026-06-1216:46 ET8-K5.07 Shareholder vote results0001689548-26-000056
2026-06-0116:28 ET8-K8.01 Other events0001689548-26-000053
2026-05-0716:16 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001689548-26-000049
2026-05-0709:06 ET10-QQuarterly reportPeriod 2026-03-310001689548-26-000047

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 19, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1689548
Tickers
PRAX
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.